afm-24,ab-101
affimed,artiva biotherapeutics
['ab101', 'afm24', 'nsclc', 'sclc', 'nkgen', '$afmd']
$afmd short review of the asco surrounding afm24 events:
-afm24mono doubtlessly shows clincal activity in nsclc (2cprs, 5sds, 47% dcr) -afm24mono terminated in favor of afm24 combos -afm24+nkgen (auto nk) terminated (in favor of afm24+ab101)
cont
Science & biotech/VC, l/s views. I/O, Cellular Tx, CAR T. No investment advice, DYODD.